Mathias Oelke

Mathias Oelke is an accomplished scientist and business professional with extensive experience in cancer research and immunotherapy. He currently serves as the Chief Scientific Officer (CSO) and Head of Preclinical Immunotherapy and Platform Development at NexImmune, Inc.1

Professional Background

With over 20 years of experience in the field of cancer research, Mathias Oelke has established himself as a leading expert in immunotherapy. His role at NexImmune, Inc. involves overseeing the company's preclinical immunotherapy efforts and platform development, which are crucial aspects of the company's mission to develop innovative cancer treatments.1

Education and Expertise

Mathias Oelke holds a Ph.D., indicating his high level of academic achievement and scientific expertise. His educational background, combined with his two decades of experience in cancer research, positions him as a valuable asset in the biotechnology industry.1

Role at NexImmune, Inc.

As the CSO and Head of Preclinical Immunotherapy and Platform Development, Mathias Oelke likely plays a pivotal role in:

• Directing the company's scientific strategy
• Overseeing research and development efforts
• Guiding the development of NexImmune's immunotherapy platform
• Collaborating with other departments to advance potential cancer treatments from preclinical stages to clinical trials

Professional Network

Mathias Oelke's LinkedIn profile (username: moelke1) serves as a platform for professional networking and sharing insights within the biotechnology and immunotherapy communities. This online presence allows him to connect with other experts in the field, potentially fostering collaborations and knowledge exchange.1